The cell surface receptor CD 33 is well known to be expressed on the surface of acute myeloid leukaemia (AML) cells and anti-CD 33 antibodies inhibit proliferation and induce apoptosis in these cancer cells.
A study of patients with AML carried out by scientists at Dundee University has identified the CD33-related receptor, Siglec 9 as a new target for the diagnosis and treatment of AML. A monoclonal antibody has been developed against this receptor. Siglec 9 has been shown to be consistently expressed on AML blast cells whilst being absent from normal bone marrow cells. The scientists says the Siglec 9 antibody has the potential to provide a more specific therapeutic target and diagnostic marker for AML.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
